What Xalatan 0.005% treats: main uses and benefits

Xalatan 0.005% (latanoprost) is an ophthalmic solution used for the management of conditions involving high pressure within the eye. Its main therapeutic domain is the reduction of heightened physiological activity specifically related to elevated intraocular pressure (IOP).

This treatment is used for conditions presenting with pressure fluctuations, specifically in patients with open-angle glaucoma and ocular hypertension. The active ingredient, latanoprost, acts by helping with the reduction of pressure. This action addresses the physiological stress on the eye and is applied in managing conditions linked to organ-specific functional stress.

This medication is utilized in clinical scenarios where it is necessary to address phases of increased ocular distress or discomfort. The primary benefit is that it assists with maintaining functional stability and contributes to improved comfort for patients experiencing these chronic eye conditions.

The goal of pressure reduction is to help patients manage fluctuations more steadily when elevated pressure might otherwise interfere with routine activities.

Quick Fact: Supports relief for conditions related to heightened intraocular pressure (IOP).

Regulatory References

1. NIH MedlinePlus Drug Information

Contraindications and Prohibited Use

The eligibility profile for Xalatan 0.005% is strictly defined by regulatory documents based on patient status and pre-existing conditions. The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to the active ingredient, latanoprost, or the preservative, benzalkonium chloride. Use is also prohibited for women who are pregnant or breastfeeding.

Absolute caution is mandated, and use is generally not recommended, for patients with active intraocular inflammation (e.g., iritis or uveitis) or active herpes simplex keratitis.

Age and Restricted Use

The medicine is approved for use in adults and the elderly. Eligibility for children is defined differently by region; while approved in some areas, its safety and effectiveness are not established in pediatric patients according to the U.S. label, and no data are available for preterm infants.

Specific patient groups require cautionary use, including those with a history of iritis/uveitis or herpes keratitis, certain lens conditions like aphakia, risk factors for macular edema, or severe asthma. Caution is also advised for patients with renal or hepatic impairment, as studies have not been conducted in these specific patient groups.

The regulatory profile for Xalatan 0.005% (Latanoprost) focuses on interactions related to local ophthalmic administration and specific population differences. A primary restriction addresses pharmacodynamic interference: the combined use of two or more prostaglandin analogues is not recommended due to the risk of paradoxical elevation in intraocular pressure (IOP) or a diminished pressure-lowering effect.

To manage potential physicochemical incompatibilities, a mandatory timing requirement is established: any other topical ophthalmic drug product must be administered at least five minutes apart from Latanoprost. This rule is necessary to prevent precipitation, which has been documented in vitro when latanoprost is mixed with certain excipients like thimerosal.

While no specific metabolic interactions with systemic medicines are formally documented, regulatory notes highlight a population-specific pharmacokinetic difference: the systemic exposure to latanoprost acid is significantly higher in pediatric patients compared to adults. Furthermore, official sources indicate insufficient information to definitively assess the safety or interaction effects of co-administering herbal remedies and supplements. The official profile is thus defined by specific constraints on local ophthalmic co-administration.

The active substance, latanoprost, functions as a prodrug. Upon topical ocular administration, the isopropyl ester is hydrolyzed by esterases in the cornea to form latanoprost acid, the biologically active metabolite. Latanoprost acid is a selective agonist for the prostanoid FP receptor (Prostaglandin F2alpha receptor) located in ocular tissues, primarily the ciliary muscle and the sclera.

Activation of the FP receptor initiates a molecular cascade involving changes in gene expression and the subsequent regulation of matrix metalloproteinases (MMPs), specifically MMP-1, MMP-3, and MMP-9. This downstream effect induces remodeling of the extracellular matrix components—including collagen, fibronectin, and laminin—within the ciliary muscle bundles. The ciliary muscle consequently relaxes and the spaces between its fibers are widened. This structural modification facilitates the increased passage of aqueous humor through the uveoscleral outflow pathway into the supraciliary and suprachoroidal spaces, modulating the resistance to fluid flow. The system-level physiological consequence of this enhanced uveoscleral outflow is a reduction in intraocular fluid volume.

How to Use Xalatan 0.005% (Latanoprost Ophthalmic Solution)

Xalatan 0.005% is administered exclusively via the topical ocular route, as a sterile eye drop solution. The standardized dosing regimen for adults, including the elderly, is the application of one drop into the affected eye or eyes once daily. The medicine is optimally used when administered in the evening.

---

Administration Schedule and Constraints

The dosage must not exceed one drop per day, as more frequent use may diminish the desired pressure-lowering effect. If a scheduled application is missed, the next regular dose should be administered as planned; an extra drop is not used to compensate for the missed one. This fixed once-daily pattern supports its role in long-term pressure management.

Usage in pediatric patients (children and adolescents) involves the same once-daily dosage as for adults.

Procedural Requirements

Certain constraints are followed during application. Soft contact lenses must be removed before instilling the drops, and reinsertion is delayed for 15 minutes following administration. If the treatment plan requires the concomitant use of other topical ophthalmic medications to reduce intraocular pressure, the medicines are administered with a separation of at least five minutes. These steps ensure the proper application and absorption of the medicine and prevent interference between different substances.

Research Evidence / Overview of Studies for Xalatan 0.005%

Research for Xalatan 0.005% (latanoprost) was studied for conditions involving elevated Intraocular Pressure (IOP). The available evidence is largely built upon comparisons made in controlled clinical settings. Studies help show what has been observed so far, providing context but not individual predictions.

---

Evidence for Use in Open-Angle Glaucoma and Ocular Hypertension

Research that studied the medicine’s role in conditions involving elevated Intraocular Pressure (IOP), such as Open-Angle Glaucoma (OAG) and Ocular Hypertension (OH), has been a key area of study. This research was evaluated in Randomized Controlled Trials (RCTs), which are considered a key standard for clinical evidence. These trials are often multi-center and double-masked.

The main focus of these short-term RCTs, typically lasting up to six months, was the measurement of Intraocular Pressure (IOP), which is an endpoint of the study. Researchers monitored the Intraocular Pressure (IOP) readings at various times throughout the day. Studies reported measurements of Intraocular Pressure (IOP), with researchers documenting the pressure readings recorded during the observation period. The documented measurements contribute to the body of evidence that was reviewed in the regulatory process.

---

Long-Term Studies and Research Uncertainty

Because eye conditions like OAG and OH are chronic, research also explored long-term patterns of observation. The primary efficacy trials often reported results over six months or less, meaning long-term IOP readings were further evaluated in longer-term observational follow-up studies, which sometimes extended up to five years. These extended studies are typically open-label.

One key limitation is the duration of primary efficacy trials. For conditions like glaucoma, the evidence for long-term visual function outcomes over the complete course of the disease is limited under double-masked, controlled conditions. Furthermore, data for certain groups remain insufficient, with limited information for long-term outcomes that specifically track the time to visual function decline in comparison to other agents in extended, masked trials.

Key Studies & References

1. NICE Guideline NG81: Glaucoma: diagnosis and management

Common questions about Xalatan 0.005% (FAQ)

Q: What is Xalatan 0.005% and what is it used for?

Xalatan 0.005% is an eye drop solution. According to regulatory documents, it's primarily used in adults to help lower high pressure within the eye, which may be associated with conditions like open-angle glaucoma or ocular hypertension. Official documents indicate it can also be used to treat increased eye pressure in pediatric patients, including children and babies, under a doctor's care.

---

Q: What is the active ingredient in Xalatan?

The active ingredient in Xalatan 0.005% is latanoprost. This substance is classified as a prostaglandin analogue. Official information indicates that latanoprost is thought to increase the natural outflow of fluid from the inside of the eye, which helps to reduce the overall eye pressure.

---

Q: How long does it take for Xalatan to start working?

According to the official product information, Xalatan may begin to lower eye pressure approximately 3 to 4 hours after the first administration. The maximum effect is typically observed 8 to 12 hours after the dose. The use of the drops should be continued according to the regimen prescribed by a healthcare professional.

---

Q: What should I do if I wear contact lenses?

Regulatory information advises that contact lenses should be removed before the application of Xalatan eye drops. This is necessary because the preservative, benzalkonium chloride, may be absorbed by soft contact lenses, potentially causing discoloration or irritation. Official labeling advises waiting at least 15 minutes after using the drops before reinserting contact lenses.

---

Q: Is it possible for Xalatan to change the color of my eye?

Yes, official product information indicates that Xalatan may slowly increase the brown pigment in the iris (the colored part of the eye) over time, which may be permanent. This change is often subtle and more commonly observed in patients with mixed-colored irises (e.g., blue-brown, green-brown). If treatment is confined to one eye, there is a potential for a difference in eye color to develop between the treated and untreated eye.

Storage and Disposal Requirements

The storage of Xalatan 0.005% is temperature-dependent and changes upon opening.

Condition	Requirement
Unopened Storage	Must be stored under refrigeration at 2 C to 8 C (36 F to 46 F). Do not freeze.
In-Use Storage	May be kept at room temperature up to mathbf25 C (77 F).
Stability	Discard six weeks after first opening.

All bottles must be stored in the original outer carton to protect the solution from light. The container should be kept tightly closed and stored out of the sight and reach of children.

For disposal, the medicine must not be placed in wastewater or household trash. Unused or expired product should be properly discarded by consulting a pharmacist or healthcare professional.